PL2748165T3 - Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych - Google Patents

Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych

Info

Publication number
PL2748165T3
PL2748165T3 PL12772808T PL12772808T PL2748165T3 PL 2748165 T3 PL2748165 T3 PL 2748165T3 PL 12772808 T PL12772808 T PL 12772808T PL 12772808 T PL12772808 T PL 12772808T PL 2748165 T3 PL2748165 T3 PL 2748165T3
Authority
PL
Poland
Prior art keywords
octan
diazabicyclo
derivatives
treatment
bacterial infections
Prior art date
Application number
PL12772808T
Other languages
English (en)
Polish (pl)
Inventor
Mahesh Vithalbhai Patel
Prasad Keshav Deshpande
Satish Bhawsar
Sachin Bhagwat
Mohammad Alam Jafri
Amit Mishra
Laxmikant Pavase
Sunil Gupta
Rajesh Kale
Sanjeev Joshi
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Publication of PL2748165T3 publication Critical patent/PL2748165T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12772808T 2011-08-27 2012-08-24 Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych PL2748165T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2412MU2011 2011-08-27
EP12772808.7A EP2748165B1 (en) 2011-08-27 2012-08-24 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.

Publications (1)

Publication Number Publication Date
PL2748165T3 true PL2748165T3 (pl) 2017-05-31

Family

ID=54289195

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12772808T PL2748165T3 (pl) 2011-08-27 2012-08-24 Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych

Country Status (17)

Country Link
US (5) US8822450B2 (enExample)
EP (1) EP2748165B1 (enExample)
JP (1) JP5666743B2 (enExample)
KR (1) KR101512738B1 (enExample)
CN (1) CN103619843B (enExample)
AU (1) AU2012303691B2 (enExample)
BR (1) BR112013028813B1 (enExample)
CA (1) CA2833241C (enExample)
DK (1) DK2748165T3 (enExample)
ES (1) ES2603198T3 (enExample)
HU (1) HUE030311T2 (enExample)
MX (1) MX348974B (enExample)
PL (1) PL2748165T3 (enExample)
PT (1) PT2748165T (enExample)
RU (2) RU2578370C2 (enExample)
WO (1) WO2013030733A1 (enExample)
ZA (1) ZA201307631B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6179588A (ja) * 1984-09-28 1986-04-23 株式会社東芝 多関節ロボツト
WO2009055557A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2365747B1 (en) 2008-10-24 2018-04-11 Cempra Pharmaceuticals, Inc. Methods for treating gastrointestinal diseases
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
WO2011032052A1 (en) 2009-09-10 2011-03-17 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
PT2748165T (pt) * 2011-08-27 2016-12-28 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
JP6208742B2 (ja) 2012-03-27 2017-10-04 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質を投与するための非経口製剤
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
AR091222A1 (es) * 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
CN104884092A (zh) 2013-01-14 2015-09-02 沃克哈特有限公司 用于治疗细菌感染的组合物和方法
KR101774132B1 (ko) * 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
MX382981B (es) * 2013-03-08 2025-03-12 Wockhardt Ltd Proceso para la preparacion de (2s, 5r)-7-oxo-6-sulfooxi-2-[((3r)-piperidin-3-carbonil)carbonil hidrazino]-1,6-diaza-biciclo[3.2.1] -octano.
EP3013830A1 (en) * 2013-03-08 2016-05-04 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
AU2014239959A1 (en) 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
KR20160020403A (ko) 2013-03-15 2016-02-23 셈프라 파마슈티컬스, 인크. 매크로라이드 항세균제들을 제조하기 위한 수렴 프로세스들
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
NZ757220A (en) 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
CN113577084A (zh) * 2013-10-22 2021-11-02 沃克哈特有限公司 包含抗菌剂的药物组合物
AU2014343327A1 (en) * 2013-10-30 2016-05-12 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
JP2017502968A (ja) * 2014-01-21 2017-01-26 ウォックハート リミテッド ７−オキソ−１，６−ジアザビシクロ［３．２．１］オクタン誘導体及び抗菌剤としてのその使用
IN2014MU00193A (enExample) * 2014-01-21 2015-08-28 Wockhardt Ltd
US9771364B2 (en) 2014-01-21 2017-09-26 Wockhardt Limited Process for preparation of (2S,5R)-6-sulphooxy-7-oxo-2-[((3R)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane
CN106900171A (zh) * 2014-03-29 2017-06-27 沃克哈特有限公司 包含头孢吡肟或舒巴坦的药物组合物
BR112016024235A2 (pt) * 2014-04-18 2017-08-15 Wockhardt Ltd composições farmacêuticas compreendendo agentes antibacterianos
SG11201700827RA (en) * 2014-08-05 2017-03-30 Cempra Pharmaceuticals Inc Powder oral suspension formulations of antibacterial agents
ME03357B (me) 2014-11-17 2019-10-20 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijsкih infekcija
EP3228620B1 (en) 2014-12-05 2020-09-02 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
WO2016116788A1 (en) * 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2016151543A1 (en) * 2015-03-25 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EP3075734A1 (en) * 2015-03-31 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2016156346A1 (en) * 2015-03-31 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002083A1 (en) * 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002086A1 (en) * 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
MX2017013792A (es) * 2015-09-16 2018-07-06 Xuanzhu Pharma Co Ltd INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.
US9951072B2 (en) 2015-10-02 2018-04-24 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017060826A1 (en) * 2015-10-06 2017-04-13 Wockhardt Limited Difluoro-(2-substituted carbamoyl-1,6-diaza-bicyclo [3.2.1] oct-6-yloxy) acetic acid compounds and their use in treatment of bacterial infections
US20180282331A1 (en) 2015-11-09 2018-10-04 Wockhardt Limited 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS
DE102016005299A1 (de) * 2016-05-02 2017-11-02 Eisele Pneumatics Gmbh & Co. Kg Verfahren zum Herstellen eines gebogenen rohrförmigen Verbindungselementes
WO2017216764A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited N-(alkanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide derivatives and their use as antibacterial agents
AU2017325863B2 (en) * 2016-09-16 2021-08-19 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
BR112019015834A2 (pt) * 2017-02-06 2020-03-31 Mutabilis Compostos, composição farmacêutica, kit e uso de um composto ou uma composição
EA202190617A3 (ru) * 2017-02-08 2021-10-29 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
US10500195B2 (en) * 2017-03-02 2019-12-10 Wockhardt Limited Antibacterial compounds
LT3630111T (lt) 2017-05-08 2022-03-10 Entasis Therapeutics, Inc. Junginiai ir būdai, skirti bakterinių infekcijų gydymui
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
WO2019105479A1 (zh) 2017-12-01 2019-06-06 南京明德新药研发股份有限公司 一种β-内酰胺酶抑制剂的晶型及其制备方法
WO2022047603A1 (en) * 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN117700415B (zh) * 2024-02-06 2024-04-30 成都四面体药物研究有限公司 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232588T2 (de) * 1991-09-26 2002-08-22 Pfizer Inc., New York Kondensierte trizyklische, stickstoffenthaltende Verbindungen als Substanz P Rezeptor Antagonisten
DK0737194T3 (da) * 1993-12-29 1999-09-27 Pfizer Diazabicykliske neurokininantagonister
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
PT2748165T (pt) * 2011-08-27 2016-12-28 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas

Also Published As

Publication number Publication date
US20150174133A1 (en) 2015-06-25
US9381200B2 (en) 2016-07-05
MX2013013887A (es) 2014-01-24
HUE030311T2 (en) 2017-04-28
EP2748165A1 (en) 2014-07-02
WO2013030733A1 (en) 2013-03-07
CA2833241A1 (en) 2013-03-07
MX348974B (es) 2017-07-04
CN103619843B (zh) 2017-01-11
CN103619843A (zh) 2014-03-05
AU2012303691A1 (en) 2013-10-31
AU2012303691B2 (en) 2014-06-19
EP2748165B1 (en) 2016-11-02
US8987297B2 (en) 2015-03-24
US20140148431A1 (en) 2014-05-29
RU2636147C1 (ru) 2017-11-21
PT2748165T (pt) 2016-12-28
DK2748165T3 (en) 2016-12-19
RU2013155902A (ru) 2015-10-10
US20150328201A1 (en) 2015-11-19
US9132133B2 (en) 2015-09-15
KR101512738B1 (ko) 2015-04-17
BR112013028813B1 (pt) 2020-10-20
US20140275018A1 (en) 2014-09-18
US8822450B2 (en) 2014-09-02
ZA201307631B (en) 2014-12-23
JP2014515041A (ja) 2014-06-26
BR112013028813A2 (pt) 2017-01-31
KR20140025525A (ko) 2014-03-04
RU2578370C2 (ru) 2016-03-27
CA2833241C (en) 2015-05-12
US8853197B1 (en) 2014-10-07
ES2603198T3 (es) 2017-02-24
NZ616542A (en) 2015-01-30
JP5666743B2 (ja) 2015-02-12
US20150005285A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
PL2748165T3 (pl) Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
PT2872510T (pt) Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
ZA201500970B (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2011113606A8 (en) Anti-infective compounds
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
WO2011085990A8 (en) Anti - infective pyrido (1,2 -a) pyrimidines
LT2739615T (lt) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanonai ir jų panaudojimas kaip vaisto
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
PT2736488E (pt) Composições farmacêuticas contendo rifaximina, processos para a sua preparação e sua utilização no tratamento de infeções vaginais
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
PL2575971T3 (pl) Połączone wyciągi roślinne do zastosowania w leczeniu zakażeń drobnoustrojami
ZA201303829B (en) 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
HK1201836A1 (en) Novel pyrrole derivatives
PL2603217T3 (pl) Nowe pochodne 6,7-dipodstawionej izochinoliny i ich zastosowanie
SI2699545T1 (sl) Novi amino-pirolinski derivati in uporaba le-teh pri preprečevanju in/ali zdravljenju metaboličnega sindroma
WO2012146736A8 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
IL226939A (en) Diarylpyridazinone derivatives, their preparation, and their use in the treatment of humans
HU1000356D0 (en) Quinoxaline derivatives and their use for the treatment of mycobacterial infections
PL2797914T3 (pl) Sulfotlenek nifuratelu do zastosowania w leczeniu infekcji bakteryjnych
HK1196617A (en) Novel purine derivatives and their use in the treatment of disease
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease